Tonix Pharmaceuticals (NASDAQ:TNXP) Director Buys $14,928.25 in Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Carolyn Taylor purchased 1,415 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average price of $10.55 per share, with a total value of $14,928.25. Following the purchase, the director directly owned 1,833 shares of the company’s stock, valued at $19,338.15. The trade was a 338.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Tonix Pharmaceuticals Stock Up 4.9%

Shares of Tonix Pharmaceuticals stock opened at $12.20 on Thursday. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $10.03 and a 52-week high of $69.97. The company has a 50 day moving average of $12.92 and a 200 day moving average of $14.87. The company has a market capitalization of $194.47 million, a P/E ratio of -0.85 and a beta of 1.67.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Monday, May 11th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative return on equity of 67.65% and a negative net margin of 839.52%.The firm had revenue of $6.88 million during the quarter, compared to analysts’ expectations of $6.13 million. As a group, research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on TNXP shares. TD Cowen raised shares of Tonix Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, May 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Monday, April 20th. Finally, Wall Street Zen cut shares of Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, April 26th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.00.

Institutional Trading of Tonix Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Tonix Pharmaceuticals by 238.1% during the third quarter. Vanguard Group Inc. now owns 556,957 shares of the company’s stock worth $13,456,000 after purchasing an additional 392,225 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Tonix Pharmaceuticals by 35.3% in the 4th quarter. Geode Capital Management LLC now owns 271,904 shares of the company’s stock valued at $4,248,000 after acquiring an additional 70,970 shares during the period. State Street Corp increased its holdings in shares of Tonix Pharmaceuticals by 25.8% in the 4th quarter. State Street Corp now owns 191,855 shares of the company’s stock valued at $2,997,000 after acquiring an additional 39,311 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at $2,895,000. Finally, Nuveen LLC increased its holdings in shares of Tonix Pharmaceuticals by 507.7% in the 4th quarter. Nuveen LLC now owns 93,402 shares of the company’s stock valued at $1,459,000 after acquiring an additional 78,033 shares during the period. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.